Balyasny Asset Management LLC Edgewise Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$15.08 - $21.23 $7.97 Million - $11.2 Million	528,594 New	528,594 $9.52 Million
Q2 2023 Aug 14, 2023	BUY	$5.71 - $10.29 $30,948 - $55,771	5,420 Added 35.56%	20,660 $160,000
Q1 2023 May 15, 2023	SELL	$6.66 - $11.33 $20,646 - $35,123	-3,100 Reduced 16.9%	15,240 $101,000
Q4 2022 Feb 14, 2023	BUY	$7.58 - $11.08 $139,017 - $203,207	18,340 New	18,340 $163,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.94B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.